Famicord AG (V3V) is rebranding its Contract Development and Manufacturing subsidiary, Famicord Cell and Gene Manufacturing, to Bramble Bio. This strategic move reflects the company’s commitment to innovation and growth in the field of novel cell therapies.

“A core element of Famicord’s vision is to enhance access to cell therapies; Bramble Bio provides development services to innovators to accelerate that access,” said Simon Boa, managing director of Bramble Bio. “By re-branding we aim to strengthen awareness of these services, which improve time-to-patient treatments for these novel and transformative class of therapeutics.”

The name “Bramble Bio” was chosen for its symbolic significance. Brambles are known for their extensive, interconnected networks of roots and branches, mirroring the company’s powerful network of 15 cryopreservation facilities, which manage >100,000 sample shipments per year. Additionally, the fruit of the bramble resembles a cluster of cells, representing the company’s focus on cellular therapies. The act of bearing fruit signifies the fruition of our clients’ efforts in developing groundbreaking treatments in tandem with our manufacturing support.

This rebranding initiative underscores Bramble Bio’s dedication to pioneering advancements in cell and gene therapies. By aligning our identity with the natural world, we emphasize a holistic and interconnected approach to healthcare innovation.

As Bramble Bio, our company aims to cultivate a robust ecosystem that fosters collaboration, research, and development in the realm of cell and gene therapies. This new identity encapsulates our mission to bring forth transformative medical solutions that improve patient outcomes worldwide.